Grade I Neuroendocrine Carcinoma
1 clinical trials · Condition
◉ Watch Grade I Neuroendocrine Carcinoma
| Record | Firm | Date |
|---|---|---|
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361) | Dwight Owen | 2018-12-31 |
Track Grade I Neuroendocrine Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.